Inactive Instrument

Cosmo Pharmaceuticals S.p.A Share Price Swiss Exchange

Equities

IT0004167463

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Cosmo Pharmaceuticals S.p.A

Financials

Sales 2023 96.72M 104M 93.6M 8.73B Sales 2024 * 264M 285M 255M 23.78B Capitalization 1.24B 1.34B 1.2B 112B
Net income 2023 1M 1.08M 968K 90.22M Net income 2024 * 124M 134M 120M 11.19B EV / Sales 2023 8.6 x
Net cash position 2023 48.44M 52.31M 46.87M 4.37B Net cash position 2024 * 120M 129M 116M 10.78B EV / Sales 2024 * 4.25 x
P/E ratio 2023
771 x
P/E ratio 2024 *
10.1 x
Employees -
Yield 2023
3.65%
Yield 2024 *
2.72%
Free-Float 44.36%
More Fundamentals * Assessed data

Latest transcript on Cosmo Pharmaceuticals S.p.A

Managers TitleAgeSince
Director of Finance/CFO 52 01/16/01
Chairman 61 01/06/01
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 01/97/01
Director/Board Member 69 01/12/01
Chairman 61 01/06/01
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
More about the company